ARUP's Laboratory Test Directory

Apolipoprotein B Mutation Detection : 0055654
[ image for: Consent Form Recommended]
Consent Form Recommended
  


Mnemonic: APO B

Methodology: 3Polymerase Chain Reaction/Fluorescence Monitoring
Performed: Mon, Thu
Reported: 2-7 days
Specimen Required: Collect:  One 5 mL lavender (EDTA) or pink (K2EDTA).  Also acceptable: green (sodium or lithium heparin), lt. blue (sodium citrate), or yellow (ACD Solution A).

Transport:  5 mL whole blood at 2-8°C.  (Min: 1 mL)

Unacceptable Conditions:  Frozen or severely hemolyzed specimens.  Serum.

Stability:  Ambient: 3 days; Refrigerated: 1 week; Frozen: Unacceptable
Reference Interval:
R3500Q Negative: This patient is negative for the R3500Q (G9775A) mutation.
R3500W Negative: This patient is negative for the R3500W (C9774T) mutation.
Interpretive Data: Familial defective apo B-100 (FDB) is an autosomal dominant disorder caused by mutations in the apo B gene that prevents the apo B-LDL complex from binding to the LDL receptor.  15% of familial hypercholesterolemia is due to this ligand-defective apolipoprotein B-100. The most common mutation, Arg3500Gln, has a frequency of 1/500-1/700 in Caucasian populations of North America and Europe. The rare Arg3500Trp mutation originally described in the Scottish population also has been identified in FDB of Asian descent (approximately 2% of  FDB patients).  Heterozygous carriers of an apo B mutation have an increased risk for coronary artery disease, although with a reduced penetrance.  40% of males and 20% of females heterozygous for these mutations develop coronary artery disease. Homozygotes or compound heterozygotes for R3500Q/R3500W are at greater risk for disease.

Mutations in other genes or other mutations in the apo B gene that may cause familial hypercholesterolemia or increased risk for coronary artery disease are not ruled out.

Patient DNA is assayed for Arg3500Gln and Arg3500Trp mutations in the apo B gene by polymerase chain reaction (PCR) and fluorescence monitoring using hybridization probes.  Sensitivity and specificity for detection of this mutation are 99.9%.
 
This test is not recommended for nonsymptomatic patients under 18 years of age.





Please refer to Statement C in the Compliance Statements section in the front of the Laboratory Test Directory.
Note:
For a complete description of the Reference Interval, please refer to ARUP's Guide to Clinical Laboratory Testing, which can be found on our Web site at www.aruplab.com.
CPT Code(s): 83890 Isolation; 83898 Amplification; 83896 x2 Nucleic acid probes; 83912 Interpretation and report - Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders.
 
 
 

 

 

 
All ARUP Sites:        www.aruplab.com     ·     www.arupconsult.com     ·     www.arup.utah.edu     ·     www.childx.org     ·     www.utahblood.org